Palmitic Acid ethyl ester
(Synonyms: 棕榈酸乙酯; Ethyl hexadecanoate) 目录号 : GC41549
A saturated fatty acid ethyl ester
Cas No.:628-97-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Palmitic acid is a common 16-carbon saturated fat that represents 10-20% of the normal human dietary fat intake. Palmitic acid also makes up approximately 25% of the total plasma fatty acids in plasma lipoproteins. Saturated fatty acids induce the expression of cyclooxygenase-2 and, after protein acylation, are used to confer lipid anchoring to a variety of signaling molecules. Palmitic acid ethyl ester is a neutral, lipid-soluble form of the free acid. It is one of the fatty acid ethyl esters that increase cytosolic Ca2+ concentration leading to pancreatic acinar cell injury due to excessive consumption of ethanol.
| Cas No. | 628-97-7 | SDF | |
| 别名 | 棕榈酸乙酯; Ethyl hexadecanoate | ||
| Canonical SMILES | CCCCCCCCCCCCCCCC(=O)OCC | ||
| 分子式 | C18H36O2 | 分子量 | 284.5 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: >100 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5149 mL | 17.5747 mL | 35.1494 mL |
| 5 mM | 0.703 mL | 3.5149 mL | 7.0299 mL |
| 10 mM | 0.3515 mL | 1.7575 mL | 3.5149 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Fabrication and Performance of Composite Microencapsulated Phase Change Materials with Palmitic Acid ethyl ester as Core
Polymers (Basel) 2018 Jul 2;10(7):726.PMID:30960651DOI:10.3390/polym10070726.
Microencapsulation of phase change materials (PCMs) could prevent the leakage of PCMs during solid⁻liquid phase change process. However, their applications are mainly limited by the compactness and thermal stability of the traditional polyurea shell microcapsules. To increase the thermal compactness and thermal stability of PCM microcapsules, tetraethylorthosilicate (TEOS) was employed to form polymer/SiO₂ composite shells to enhance the mechanical performance of polyurea and polyurethane microcapsule via interfacial polymerization and in situ polymerization. The morphology and chemical components of the microcapsules were characterized by field-emission scanning electron microscope (FE-SEM) and Fourier transform infrared (FT-IR) spectroscopy, respectively. The thermal properties of the microcapsules were investigated by differential scanning calorimetry (DSC) and thermal gravity analysis (TGA). The results showed the smoothness and compactness of both polyurea⁻SiO₂ and polyurethane⁻SiO₂ microcapsules enhanced slightly, when compared with that without TEOS addition. Moreover, the SiO₂ composite shell had good effect on thermal compactness, as the weight loss rate of polyurea⁻SiO₂ microcapsules and polyurethane⁻SiO₂ microcapsules decreased 3.5% and 4.1%, respectively.
Fatty-Acid-Rich Agave angustifolia Fraction Shows Antiarthritic and Immunomodulatory Effect
Molecules 2022 Oct 24;27(21):7204.PMID:36364031DOI:10.3390/molecules27217204.
Agave angustifolia is a xerophytic species widely used in Mexico as an ingredient in sweet food and fermented beverages; it is also used in traditional medicine to treat wound pain and rheumatic damage, and as a remedy for psoriasis. Among the various A. angustifolia extracts and extract fractions that have been evaluated for their anti-inflammatory effects, the acetonic extract (AaAc) and its acetonic (F-Ac) and methanolic (F-MeOH) fractions were the most active in a xylene-induced ear edema model in mice, when orally administered. Four fractions resulting from chemically resolving F-Ac (F1-F4) were locally applied to mice with phorbol 12-myristate 13-acetate (TPA)-induced ear inflammation; F1 inhibited inflammation by 70% and was further evaluated in a carrageenan-induced mono-arthritis model. When administered at doses of 12.5, 25, and 50 mg/kg, F1 reduced articular edema and the spleen index. In addition, it modulated spleen and joint cytokine levels and decreased pain. According to a GC-MS analysis, the main components of F1 are fatty-acid derivatives: palmitic acid methyl ester, Palmitic Acid ethyl ester, octadecenoic acid methyl ester, linoleic acid ethyl ester, and oleic acid ethyl ester.
Synthesis of lipophilic arbutin ester by enzymatic transesterification in high pressure carbon dioxide
Enzyme Microb Technol 2021 Aug;148:109818.PMID:34116761DOI:10.1016/j.enzmictec.2021.109818.
In this study, a novel one-step enzymatic acylation was developed for the synthesis of hydrophobic arbutin ester, by using supercritical carbon dioxide (SC-CO2) as the reaction solvent. Immobilized Novozym 435 from Candida antarctica was identified as the best biocatalyst for producing arbutin palmitate through transesterification between arbutin and Palmitic Acid ethyl ester in SC-CO2. A transesterification yield of 85.21 % was obtained in batch operation using Palmitic Acid ethyl ester as the acyl donor, hexane/propylene glycol as the co-solvent and Novozym 435 as the enzyme at 10 MPa and 60 °C for 20 h in SC-CO2. The yield of arbutin palmitate increased with increasing temperature over the range of 40-60 °C in the current study. Operating at an arbutin/Palmitic Acid ethyl ester molar ratio of 5.0, the conversion of arbutin decreased, probably due to an inhibitory effect of the high concentration of Palmitic Acid ethyl ester on the enzyme. The 38 % original enzyme activity of Novozym 435 was maintained after being used for 3 cycles (60 h) under optimized conditions.